FFA
LCTX icon

Farther Finance Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

Farther Finance Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.08K Buy
1,126
+582
+107% +$644 ﹤0.01% 5565
2026
Q2 		$713 Hold
544
– – ﹤0.01% 5464
2026
Q1 		$865 Buy
544
+455
+511% +$767 ﹤0.01% 5144
2025
Q4 		$149 Buy
89
+5
+6% +$9 ﹤0.01% 5254
2025
Q3 		$142 Hold
84
– – ﹤0.01% 4788
2025
Q2 		$76 Sell
84
-345
-80% -$205 ﹤0.01% 4338
2025
Q1 		$176 Buy
+429
New +$252 ﹤0.01% 3972

Other funds holding LCTX

DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
HA
Hofer & Associates Thousand Oaks, California $143M AUM 11.29% 1-Year Est. Return
RCWM
Red Crane Wealth Management San Francisco, California $143M AUM 13.63% 1-Year Est. Return
CWM
Connecticut Wealth Management Farmington, Connecticut $2.73B AUM 14.39% 1-Year Est. Return
CD
Chapin Davis Baltimore, Maryland $520M AUM 117.57% 1-Year Est. Return
FCMT
Founders Capital Management (Texas) Houston, Texas $220M AUM 46.36% 1-Year Est. Return
AP
Anchyra Partners Atlanta, Georgia $477M AUM 34.33% 1-Year Est. Return
EM
ELCO Management New York $213M AUM 25.23% 1-Year Est. Return
PP
Pacifica Partners Surrey, Canada $332M AUM 43.09% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Farther Finance Advisors's LCTX Position: Q3 2026 in Review

Farther Finance Advisors increased its Lineage Cell Therapeutics (LCTX) stake by 107% in Q3 2026, buying an estimated $644 and bringing the position to 1,126 shares worth $1.08K. The position accounts for ﹤0.01% of the portfolio, ranked #5565.

Farther Finance Advisors first reported a position in LCTX in Q1 2025 and has held it in 7 quarters since. 11 funds tracked by Wall St. Rank hold LCTX as of Q3 2026.

  • Farther Finance Advisors held 1,126 shares of Lineage Cell Therapeutics worth $1.08K as of Q3 2026.
  • Farther Finance Advisors bought 582 Lineage Cell Therapeutics shares in Q3 2026, an estimated $644.
  • Lineage Cell Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #5565 holding.
  • Farther Finance Advisors first reported a position in Lineage Cell Therapeutics in Q1 2025 and has held it in 7 quarters since.
  • 11 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.